Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.

Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Leighl, lung cancer expert from Princess Margaret Hospital in Toronto, continued her summary of the leading highlights in lung cancer from 2012 with coverage of new information on XALKORI for patients with either an ALK rearrangement or the newly identified ROS-1 rearrangement.  

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Here's a video I just did in response to my recent spate of molecular marker studies I've sent in the last 4-6 weeks that have come back with quite a few positive results for an EGFR mutation or ALK rearrangement, as well as one patient positive for a ROS1 rearrangement.  For each of these patients, the results have had a major impact in the opportunity for them to receive an oral therapy with a high probability of response, and in a few cases, we've already seen a significant improvement.